Expression of cyclin Y after treatment with icaritin and cisplatin in the lung cancer cell lines
, 1, 1, 2, 3, 1
Abstract
Introduction: Cyclin Y has been defined as a protein that is involved in both – cell cycle control and transcription process. The aim of this study was to determine the association between cyclin Y expression and events triggered by cisplatin and icaritin treatment. Methods: Apoptosis and the cell cycle distribution were evaluated by flow cytometry. Proteins expression was measured by conducting a immunofluorescence staining. The study revealed that icaritin induces apoptosis and cell cycle arrest in the G2/M phase in A549 and H1299 cells. Results and conclusions The results of the study showed that the cells of the A549 and H1299 lines were sensitive to cisplatin and icaritin. Furthermore, it was shown that cisplatin increased the percentage of cells of both lines in the G2/M phase of the cell cycle. The expression of the cyclin Y increased with increasing doses of cisplatin and icaritin. The cyclin Y upregulation was correlated with cell cycle arrest, an increase in the percentage of apoptotic cells, and the inhibition of the migration potential of cells of both lines.
Keywords: cyclin Ylung cancericaritincisplatin
References
- Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022; 23(1): 74–88.
- Heuvel Sv. Cell-cycle regulation. WormBook. 2005.
- Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013; 140(15): 3079–3093.
- Liu D, Finley RL. Cyclin Y is a novel conserved cyclin essential for development in Drosophila. Genetics. 2010; 184(4): 1025–1035.
- Cho E, Kim DH, Hur YN, et al. Cyclin Y inhibits plasticity-induced AMPA receptor exocytosis and LTP. Sci Rep. 2015; 5: 12624.
- Jiang M, Gao Y, Yang T, et al. Cyclin Y, a novel membrane-associated cyclin, interacts with PFTK1. FEBS Lett. 2009; 583(13): 2171–2178.
- Mikolcevic P, Sigl R, Rauch V, et al. Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Mol Cell Biol. 2012; 32(4): 868–879.
- Wang X, Jia Y, Fei C, et al. Activation/Proliferation-associated Protein 2 (Caprin-2) Positively Regulates CDK14/Cyclin Y-mediated Lipoprotein Receptor-related Protein 5 and 6 (LRP5/6) Constitutive Phosphorylation. J Biol Chem. 2016; 291(51): 26427–26434.
- Shi K, Ru Q, Zhang C, et al. Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells. Med Sci Monit. 2018; 24: 1642–1653.
- Żuryń A, Krajewski A. Icaritin induces apoptosis and downregulates RhoA/ROCK pathway in the A549 adenocarcinoma cell line. Medical Research Journal. 2022; 7(3): 242–248.
- Debela DT, Muzazu SGy, Heraro KD, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021; 9: 20503121211034366.
- Costantini S, Budillon A. New Prognostic and Predictive Markers in Cancer Progression. Int J Mol Sci. 2020; 21(22).
- van Gool AJ, Bietrix F, Caldenhoven E, et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev Drug Discov. 2017; 16(9): 587–588.
- Sarin N, Engel F, Kalayda GV, et al. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS One. 2017; 12(7): e0181081.
- Liu Y, Shi L, Liu Y, et al. Activation of PPARγ mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme. Biomed Pharmacother. 2018; 100: 358–366.
- Wu JS, Jiang J, Chen BJ, et al. Plasticity of cancer cell invasion: Patterns and mechanisms. Transl Oncol. 2021; 14(1): 100899.
- Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol. 2004; 16(1): 14–23.
- Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6): 1420–1428.
- Wang H, Guo S, Kim SJ, et al. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics. 2021; 11(5): 2442–2459.
- Xu Bo, Jiang C, Han H, et al. Icaritin inhibits the invasion and epithelial-to-mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF-1α signalling. Clin Exp Pharmacol Physiol. 2015; 42(12): 1296–1307.
- Vara-Ciruelos D, Russell FM, Hardie DG. The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde? . Open Biol. 2019; 9(7): 190099.
- Konieczny P, Adamus T, Sułkowski M, et al. Impact of AMPK on cervical carcinoma progression and metastasis. Cell Death Dis. 2023; 14(1): 43.
- Fatkhutdinov N, Sproesser K, Krepler C, et al. Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res. 2016; 14(9): 767–775.
- Wang L, Meng L, Wang Xw, et al. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014; 35(3): 1899–1906.